Search

Your search keyword '"Hogg D"' showing total 290 results

Search Constraints

Start Over You searched for: Author "Hogg D" Remove constraint Author: "Hogg D" Database Unpaywall Remove constraint Database: Unpaywall
290 results on '"Hogg D"'

Search Results

1. Development, validation and outcomes associated with a risk prediction algorithm for incident atrial fibrillation: retrospective national cohort study of 2 081 139 individuals

2. Kepler K2Campaign 9 – II. First space-based discovery of an exoplanet using microlensing

6. 856P Characterization of patients with brain metastases from metastatic uveal melanoma

7. 831P Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp

8. 834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)

10. 1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma

13. 1144P Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma

20. 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

21. Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs

23. Yule-Simpson’s paradox in Galactic Archaeology

24. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

25. Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

27. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

28. Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone

29. Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination

30. PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

31. Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

36. 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

42. A Phase Ii Study (Nct01883323) Evaluating the Infusion of Autologous Tumor-Infiltrating Lymphocytes (Til) and Low-Dose Interleukin-2 (Il-2) Therapy Following Non-Myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients with Metastatic Melanoma

44. Baryon acoustic oscillations in the Lyαforest of BOSS quasars

45. The Sloan Digital Sky Survey quasar catalog: ninth data release

48. Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma

49. Essai multicentrique, ouvert et randomisé de phase III (BRIM3) évaluant vemurafenib (V) vs dacarbazine (D) dans le mélanome muté BRAFV600E

Catalog

Books, media, physical & digital resources